Consistent with our results in the HMLE system, basal breast cancer cells had lower overall ROS than luminal cells, and addition of the PERK inhibitor caused a dramatic increase in ROS levels in basal cells but not luminal cells (Figure 3f). The gene discussed is EIF2AK3; the disease is breast carcinoma.